Infliximab Maintenance Treatment Reduces Hospitalizations, Surgeries, and Procedures in Fistulizing Crohn's Disease

Lichtenstein, Gary

doi:10.1016/s0739-5930(08)70334-9

Cited by 114 publications

(149 citation statements)

References 4 publications

Supporting

Mentioning

142

Contrasting

Unclassified

Order By: Relevance

“…Median time for loss of response to INF was greater than 54 weeks in both groups on the maintenance dosing schedule. A similar study examined maintenance treatment of moderate to severe CD patients [48]. Maintenance dosing reduced the number of surgeries, hospitalizations, and procedures (p<0.05 for all outcomes).…”

Section: Infmentioning

confidence: 99%

TNFα blockade in human diseases: An overview of efficacy and safety

Lin

Ziring

Desai

et al. 2008

Clinical Immunology

233

188

View full text Add to dashboard Cite

show abstract

Section: Infmentioning

confidence: 99%

TNFα blockade in human diseases: An overview of efficacy and safety

Lin

Ziring

Desai

et al. 2008

Clinical Immunology

233

188

View full text Add to dashboard Cite

show abstract

“…Infliximab, a chimeric monoclonal antibody that binds with high affinity and specificity to TNF-a, has been demonstrated to be effective in both induction and maintenance therapy for patients with moderately to severely active CD, and is presently the only biological compound approved for CD therapy. 15,16,48,49 Newer therapeutic monoclonal antibodies targeting interferon (IFN)-g, 50,51 IL-6 receptor, 18 IL-12 p40, 52 and a4-integrin 53 have also been developed, and clinical trials to evaluate the safety and efficiency of those agents for the treatment of IBD are being conducted. Although the development of therapeutic monoclonal antibodies is one of the most important advances in the care of IBD patients during the past decade, current therapies based on such biological agents are not entirely as effective as expected, as several untoward effects including immunogenicity, infusion reactions, and other serious adverse events have been reported.…”

Section: Effects Of Decoy Odns On Expression Of Proinflammatory Cytokmentioning

confidence: 99%

Decoy oligodeoxynucleotide targeting activator protein-1 (AP-1) attenuates intestinal inflammation in murine experimental colitis

Moriyama

Ishihara

Rumi

et al. 2008

Laboratory Investigation

View full text Add to dashboard Cite

Various therapies are used for inflammatory bowel diseases (IBD), though none seem to be extremely effective. AP-1 is a major transcription factor that upregulates genes involved in immune and proinflammatory responses. We investigated decoy oligodeoxynucleotide (ODN) targeting AP-1 to prevent dextran sulfate sodium (DSS)-induced colitis in mice. Functional efficacies of synthetic decoy and scrambled ODNs were evaluated in vitro by a reporter gene luciferase assay and measuring flagellin-induced IL-8 expression by HCT-15 cells transfected with ODNs. Experimental colitis was induced in mice with a 2.5% DSS solution in drinking water for 7 days, and decoy or scrambled ODNs were intraperitoneally injected from days 2 to 5. Colitis was assessed by weight loss, colon length, histopathology, and detection of myeloperoxidase (MPO), IL-1b, and TNF-a in colon tissue. Therapeutic effects of AP-1 and NF-kB decoy ODNs were compared. Transfection of AP-1 decoy ODN inhibited AP-1 transcriptional activity in reporter assays and flagellin-induced IL-8 production in vitro. In mice, AP-1 decoy ODN, but not scrambled ODN, significantly inhibited weight loss, colon shortening, and histological inflammation induced by DSS. Further, AP-1 decoy ODN decreased MPO, IL-1b, and TNF-a in colonic tissue of mice with DSS-induced colitis. The AP-1 decoy therapeutic effect was comparable to that of NF-kB decoy ODN, which also significantly decreased intestinal inflammation. Double-strand decoy ODN targeting AP-1 effectively attenuated intestinal inflammation associated with experimental colitis in mice, indicating the potential of targeting proinflammatory transcription factors in new therapies for IBD.

show abstract

“…Biological treatment with TNF-alfa inhibitors improve the condition of intestinal mucosa, and diminish the number of hospital admissions and surgeries [20,26]. The results of the treatment of fistulas are also improved [6,13,17,19,[27][28][29][30][31]. However, there is a lack of credible studies on the prevention of fistulas in Crohn's disease in children.…”

Section: Discussionmentioning

confidence: 99%

“…Great expectations are connected to biological treatment. Numerous authors analyzing the results of infliximab therapy in adults with Crohn's disease observed that in more than a half of the patients fistulas were completely closed after induction therapy; slightly worse results were seen after maintenance therapy [19,27,29,30,35,36]. Crandall et al [37] obtained good results with infliximab in treating Crohn's disease with fistulas in children at 54 th week of the treatment.…”

Section: Discussionmentioning

confidence: 99%

Induction and Maintenance Infliximab Therapy for the Treatment of Crohn’s Disease with Perianal Fistulas in Children: Retrospective, Multicenter Study

Iwańczak¹,

Ryżko²,

Jankowski³

et al. 2016

Adv Clin Exp Med

View full text Add to dashboard Cite

Background. Infliximab is a biological drug used for the treatment of Crohn's disease in children. Objectives. The aim of this retrospective study was the estimation of effectiveness and safety of infliximab in the treatment of Crohn's disease with perianal fistulas in children. Material and Methods. Analysis comprised 50 children with Crohn's disease with perianal fistulas aged 9 to 18 years (16 girls and 34 boys) who failed to respond to conventional therapy. The children were divided into two groups: the first group contained 23 children with simple fistulas and the second -27 children with complex fistulas. All children were treated with infliximab, administered in the dose of 5 mg per kilogram of the body mass. In the induction phase infliximab was administered at weeks 0, 2 and 6 and after clinical response in maintenance phase the drug was administered every 8 weeks; together for 12 months. Results. In 76% of children after induction therapy with infliximab and in 71.87% after maintenance therapy the complete closure of fistula occurred. During the first year after the treatment a recurrence of a fistula was observed in 30.43% of the children. In two children anaphylactic shock was observed during injection of infliximab. The remaining children tolerated the drug well. Conclusions. The treatment with infliximab was effective in the majority of fistulazing Crohn's disease and caused the closure of perianal fistula which improved quality of life (Adv Clin Exp Med 2016, 25, 3, 523-530).

show abstract

Infliximab Maintenance Treatment Reduces Hospitalizations, Surgeries, and Procedures in Fistulizing Crohn's Disease

Cited by 114 publications

References 4 publications

TNFα blockade in human diseases: An overview of efficacy and safety

TNFα blockade in human diseases: An overview of efficacy and safety

Decoy oligodeoxynucleotide targeting activator protein-1 (AP-1) attenuates intestinal inflammation in murine experimental colitis

Induction and Maintenance Infliximab Therapy for the Treatment of Crohn’s Disease with Perianal Fistulas in Children: Retrospective, Multicenter Study

Contact Info

Product

Resources

About